Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

New Culture Technique Will Promote the Study of Leukemic Stem Cells

By BiotechDaily International staff writers
Posted on 02 Apr 2014
Image: Acute myeloid leukemia cells presenting anomalies in standard growth conditions (top). Acute myeloid leukemia cells preserving their leukemic cell features following in vitro culture with the two chemical molecules referred to in the study (below) (Photo courtesy of the Université de Montréal).
Image: Acute myeloid leukemia cells presenting anomalies in standard growth conditions (top). Acute myeloid leukemia cells preserving their leukemic cell features following in vitro culture with the two chemical molecules referred to in the study (below) (Photo courtesy of the Université de Montréal).
A multidisciplinary team of cancer researchers has developed a method for maintaining leukemic stem cells (LSCs) in culture, which will aid in the study of this class of cancer cells and the development of new drugs.

It has proven difficult to study LSCs, as currently available culture conditions do not prevent their spontaneous differentiation into full-blown acute myeloid leukemia (AML) cells. To overcome these constraints the “Leucégène” research group of investigators at the Université de Montréal (Canada) conducted a high-throughput chemical screen to identify small molecules that could inhibit differentiation and support LSC activity in vitro.

They reported in the February 23, 2014, online edition of the journal Nature Methods that they were able to identify two chemical compounds that, when added to the culture medium, could maintain functional human LSCs alive for at least seven days in vitro. One of the compounds suppressed the aryl-hydrocarbon receptor (AhR) pathway, which is inactive in vivo but rapidly activated ex vivo in AML cells. The other compound, UM729, collaborated with AhR suppressors in preventing AML cell differentiation.

These findings provide newly defined culture conditions for improved ex vivo culture of human LSCs and primary AML cells. “This research breakthrough demonstrates the advantage of working in a multidisciplinary team like the “Leucégène” research group,” said senior author Dr. Guy Sauvageau, professor of medicine at the Université de Montréal. “Access to cells of leukemia patients and to IRIC’s [The Institute for Research in Immunology and Cancer of the Université de Montréal] state-of-the-art facilities are also key factors in pursuing ground-breaking research.”

Related Links:

Université de Montréal



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.